Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.3K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.3K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.1K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.1K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

726
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
726
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.9K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.9K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

328
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
328
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

964
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
964

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anatomical and radiographic stroke topography predicts ventricular and atrial ectopic burden.

Heart & lung : the journal of critical care·2026
Same author

Artificial Intelligence in the Assessment of Heart Rate Variability as an Instrument to Understand the Connection Between Psychologic and Psychiatric Conditions and the Heart.

Bioengineering (Basel, Switzerland)·2026
Same author

Interleukin-17, Interleukin-18, T Regulatory Cells, and T-Helper 17 (Th17) Cells Play a Role in Heart Failure: A Systematic Review and Meta-Analysis.

Cardiology research and practice·2026
Same author

Neurodegenerative biomarkers and heart failure: is there a neurodegenerative cardiomyopathy? a systematic review and meta-analysis.

Journal of geriatric cardiology : JGC·2026
Same author

Blood pressure responses to captive bolt and electrical stunning in sheep and cattle: A systematic review.

Veterinary journal (London, England : 1997)·2026
Same author

Epigenomics and Epigenetics in Heart Failure with Preserved Ejection Fraction.

Heart failure clinics·2026
Same journal

Reply Letter.

Cardiology·2026
Same journal

Aortic Valve Sclerosis: More Than an Incidental Echocardiographic Finding.

Cardiology·2026
Same journal

Can resting segmental strain identify obstructive coronary artery disease in chronic coronary syndrome patients referred to CABG?

Cardiology·2026
Same journal

Mortality Impact of Stroke and Major Bleeding Across the Ejection Fraction Spectrum in Patients Hospitalized for Acute Heart Failure With Prevalent Atrial Fibrillation.

Cardiology·2026
Same journal

Impact of Inflammatory Disorders on Outcomes in Acute Heart Failure: A Nationwide Analysis.

Cardiology·2026
Same journal

Predictors and Clinical Impact of Tricuspid Regurgitation After Pericardiectomy for Constrictive Pericarditis.

Cardiology·2026
See all related articles

Related Experiment Video

Updated: Oct 5, 2025

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

13.3K

Hypocalcemia-Induced QT Interval Prolongation.

Jacky K K Tang1, Simon W Rabkin1,2

  • 1Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Cardiology
|January 25, 2022
PubMed
Summary
This summary is machine-generated.

Hypocalcemia, or low calcium levels, can cause a prolonged QT interval, increasing arrhythmia risk. Correcting calcium levels effectively shortened the QT interval in a patient case study.

Keywords:
ElectrocardiographyHypocalcemiaQT interval

More Related Videos

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

3.3K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.4K

Related Experiment Videos

Last Updated: Oct 5, 2025

Electrocardiogram Recordings in Anesthetized Mice using Lead II
04:16

Electrocardiogram Recordings in Anesthetized Mice using Lead II

Published on: June 20, 2020

13.3K
High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
10:01

High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening

Published on: March 31, 2022

3.3K
Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

6.4K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Case Study

Background:

  • A patient with multiple comorbidities presented with a significantly prolonged QT interval.
  • The prolonged QT interval was identified as being in the 99th percentile for the general population.

Observation:

  • The patient's prolonged QT interval was associated with hypocalcemia.
  • Interventions included reducing furosemide dosage and administering calcium supplementation.
  • These interventions led to increased serum calcium levels and a shortened QT interval.

Findings:

  • Hypocalcemia is a likely cause of corrected QT interval prolongation via a calcium-dependent inactivation mechanism on L-type calcium channels.
  • Reduced extracellular calcium prolongs ventricular myocyte repolarization, potentially leading to early afterdepolarizations and ventricular arrhythmias.
  • Disturbances in intracellular myocardial calcium handling, such as those seen in hypocalcemia, play a role in arrhythmogenesis.

Implications:

  • Hypocalcemia is an under-recognized cause of QT prolongation.
  • Clinicians should consider hypocalcemia in patients with incidental findings of a prolonged QT interval.
  • Understanding the role of calcium in cardiac electrophysiology is crucial for managing arrhythmias.